PMVP +20% on phase-1 data for p53-mutation corrector at ASCO: https://finance.yahoo.com/news/pmv-pharmaceuticals-announces-initial-pc14586-210500373.html Even after today’s bounce, PMVP is -60% from its closing price on the first day of post-IPO trading in late 2020.